United States Steel Statistics
Total Valuation
HeartSciences has a market cap or net worth of $8.17 million. The enterprise value is $10.06 million.
Important Dates
The next estimated earnings date is Thursday, September 11, 2025, after market close.
| Earnings Date | Sep 11, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
HeartSciences has 2.28 million shares outstanding. The number of shares has increased by 166.16% in one year.
| Current Share Class | 2.28M |
| Shares Outstanding | 2.28M |
| Shares Change (YoY) | +166.16% |
| Shares Change (QoQ) | +8.60% |
| Owned by Insiders (%) | 3.76% |
| Owned by Institutions (%) | 3.66% |
| Float | 2.19M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1,878.56 |
| Forward PS | n/a |
| PB Ratio | 19.62 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2,312.38 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.59, with a Debt / Equity ratio of 14.55.
| Current Ratio | 0.59 |
| Quick Ratio | 0.30 |
| Debt / Equity | 14.55 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -16.69 |
Financial Efficiency
Return on equity (ROE) is -233.04% and return on invested capital (ROIC) is -90.44%.
| Return on Equity (ROE) | -233.04% |
| Return on Assets (ROA) | -76.07% |
| Return on Invested Capital (ROIC) | -90.44% |
| Return on Capital Employed (ROCE) | -1,607.20% |
| Revenue Per Employee | $290 |
| Profits Per Employee | -$584,349 |
| Employee Count | 15 |
| Asset Turnover | 0.00 |
| Inventory Turnover | 0.00 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +13.25% in the last 52 weeks. The beta is 2.58, so HeartSciences's price volatility has been higher than the market average.
| Beta (5Y) | 2.58 |
| 52-Week Price Change | +13.25% |
| 50-Day Moving Average | 3.78 |
| 200-Day Moving Average | 3.44 |
| Relative Strength Index (RSI) | 48.21 |
| Average Volume (20 Days) | 149,082 |
Short Selling Information
The latest short interest is 196,411, so 8.63% of the outstanding shares have been sold short.
| Short Interest | 196,411 |
| Short Previous Month | 192,283 |
| Short % of Shares Out | 8.63% |
| Short % of Float | 8.97% |
| Short Ratio (days to cover) | 1.24 |
Income Statement
In the last 12 months, HeartSciences had revenue of $4,350 and -$8.77 million in losses. Loss per share was -$9.34.
| Revenue | 4,350 |
| Gross Profit | 2,470 |
| Operating Income | -8.35M |
| Pretax Income | -6.61M |
| Net Income | -8.77M |
| EBITDA | -8.31M |
| EBIT | -8.35M |
| Loss Per Share | -$9.34 |
Full Income StatementBalance Sheet
The company has $1.10 million in cash and $2.99 million in debt, giving a net cash position of -$1.89 million or -$0.83 per share.
| Cash & Cash Equivalents | 1.10M |
| Total Debt | 2.99M |
| Net Cash | -1.89M |
| Net Cash Per Share | -$0.83 |
| Equity (Book Value) | 205,171 |
| Book Value Per Share | 0.18 |
| Working Capital | -1.53M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$7.41 million and capital expenditures -$3,157, giving a free cash flow of -$7.42 million.
| Operating Cash Flow | -7.41M |
| Capital Expenditures | -3,157 |
| Free Cash Flow | -7.42M |
| FCF Per Share | -$3.26 |
Full Cash Flow StatementMargins
| Gross Margin | 56.78% |
| Operating Margin | -192,013.13% |
| Pretax Margin | -201,499.52% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
HeartSciences does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -166.16% |
| Shareholder Yield | -166.16% |
| Earnings Yield | -107.26% |
| FCF Yield | -90.75% |
Analyst Forecast
The average price target for HeartSciences is $13.00, which is 262.12% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $13.00 |
| Price Target Difference | 262.12% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on May 17, 2024. It was a reverse split with a ratio of 1:100.
| Last Split Date | May 17, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:100 |
Scores
HeartSciences has an Altman Z-Score of -31.7 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -31.7 |
| Piotroski F-Score | 1 |
